A randomized, open-label, parallel-controlled, multicenter phase III clinical study of CD25 monoclonal antibody in preventing acute graft-versus-host disease after haploidentical hematopoietic stem cell transplantation (ChiCTR) - Oct 16, 2026 - P3 | N=186 | Not yet recruiting | Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of
New P3 trial • Acute Graft versus Host Disease • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Malignancies • Immunology • Transplantation
|